Catalent and Cevec team-up to offer protein CDMO services
![Catalent and Cevec's new protein CDMO services](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/3/4/8/3/3223843-1-eng-GB/Catalent-and-Cevec-team-up-to-offer-protein-CDMO-services.png)
The alliance will combine Catalent’s GPEx gene-insertion tech with Cevec’s CAP cell line protein expression platform, derived from primary human aminocytes.
The deal follows a joint-study for complex protein production, which saw “record” yields of non-antibody proteins produced in a human expression system.
In a joint statement, the firms said they “achieved a manufacturing yield of over three grams per ltr for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative proprietary technologies.”
Kent Payne, VP and general manager of Catalent’s biologics business said: “We look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”